FORM - 2 THE PATENTS ACT, 1970 (39 OF 1970) AND THE PATENTS RULES, 2003 (As Amended) COMPLETE SPECIFICATION (See section 10; rule 13) "A Novel Process for Preparation of Polysaccharides" Serum Institute of India Ltd., a corporation organized and existing under the laws of India, of 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411 028 Maharashtra India. The following specification particularly describes the nature of this invention and the manner in which it is to be performed: Title: A novel process for preparation of polysaccharides BACKGROUND OF THE INVENTION The pathogenic bacteria classified as Streptococcus pneumoniae (pneumococci, Pn) have been subdivided into 84 antigenic serotypes, based on the capsular polysaccharide (PnPs) of the organism. Disease states attributable to these organisms include pneumonia, meningitis, otitis media, bacteremia and acute exacerbations of chronic bronchitis, sinusitis, arthritis, and conjunctivitis. The preponderance of these diseases, however, are caused by a limited subset of the 84 known isolates. Thus, a polyvalent vaccine containing the PnPs from the most prevalent and pathogenic isolates of the organism can provide protection against a very high percentage of the most frequently reported pathogens of this class. The PnPs utilized for preparing conjugate vaccines are always associated with a substantial amount of a common impurity/contaminant, called C-Polysaccharide(O Ps).Although the presence of the C-polysaccharide contaminant does not interfere with the immune responses against the type specific antigens, production of anti-C-polysaccharide antibodies may correlate with the tissue destruction observed in some unresolved pneumococcal infections.The C-Ps content could compromise the efficacy of a pneumococcal conjugate vaccine. The C-Ps has also been classified as a polysaccharide impurity by WHO, refer WHO TRS 19-23 October 2 009(Recommendations to assure the quality,safety and efficacy of pneumococcal conjugate vaccines}. Thus a need for improving purity of the polysaccharides i.e. reduction in contamination with group-specific C-polysaccharide always exist in the industry. US Patent 4242501 claims ammonium sulphate based polysaccharide precipitation, wherein C-Polysaccharide content is reduced to less than 0.5%.The purification process however consists of 12 steps and utilizes alcohol for precipitation also. US Patent 5623057 claims C-polysaccharide content less than 3% by utilizing Isopropyl alcohol based PnPs purification and also employs ion exchange chromatography before or after partial hydrolysis (Sonic or thermal} of polysaccharide . US Patent 5714354 claims an " alcohol free " PnPs purification process, utilizes CTAB (1-4%} , hydroxyapatite chromatography and ion exchange chromatography .Here CTAB step removes majority of C-polysaccharide. US Patent 5847112 claims C-Ps reduction by 3-20 fold, However here PnPs purification comprises of multiple isopropyl alcohol and cetavlon steps. 1572/MUM/2010 claims deoxycholate & Hydrophobic interaction chromatography based(i.e alcohol and CTAB free) purification.Here C-Ps content is 4-14%. The prior art methods utilize CTAB ,alcohol and are multi-step. CTAB has been previously utilized for selectively precipitation of polysaccharide .however CTAB is a hazardous chemical. Further removal of CTAB from precipitated PnPs requires ethanol. Use of ethanol during pneumococcal polysaccharide purification is associated with following operational problems: a) Use of ethanol requires a flame proof facility; b) designing such facility is very costly , c) ethanol is under custom/Govt. Regulation, d) ethanol is hazardous , e} effluent treatment is very difficult f) amount of ethanol requirement is huge and it's is almost ~ 4-6 L of ethanol per litre of process material and g)requires costly charcoal filtration and lyophilization steps. The prior art methods that utilize ethanol and CTAB steps require 77-90 hrs to achieve the C-Ps-reduced polysaccharide preparation and hence are laborious. Surprisingly we have found that when a preferred sinle or multiple step chromatography is utilized for preparation of pneumococcal polysaccharides, a substantial reduction of group specific C-Ps content is observed .The said process being alcohol and CTAB free is easily scalable, cost efficient and less laborious. SUMMARY OF THE INVENTION The invention is an alcohol and CTAB free method for the purification of pneumococcal polysaccharides which are used in the preparation of polysaccharide vaccines. The instant process utilizes chromatographic separation of C-Ps from the polysaccharides (PnPs)on the basis of differences in their net surface charge. The process is a generic process to purify pneumococcal polysaccharides. PnPs prepared by the instant process shows recovery of about 60 to 70%,wherein C-polysaccharide contamination reduction is of 1 to 5 fold as compared to the C-Ps content of post-Hydrophobic interaction chromatography (HIC) or pre ion exchange chromatography(IEX),protein contamination is less than 1% and nucleic acid contamination is less than l%.The said process has been carried out at Research,Pilot and commercial scale. This process can purify polysaccharides with 80-90% less time consumed & 90% less cost when compared with CTAB/Alcohol based methods. DESCRIPTION OF THE DRAWINGS Figures for HIC followed by Ion exchange chromatography Fig.l Pneumococcal polysaccharide 19F-HPLC profile of pre-HIC Fig. 2 Pneumococcal polysaccharide 19F-HPLC profile of post Hydrophobic Interaction Chromatography (HIC) Fig.3 NMR of 19F PnPs-post-HIC chromatography Fig.4 Ion exchange chromatogram of HIC-purified PnPs Fig. 5 HPLC profile of 19F PnPs after IEX (final PnPs/example 1) Fig.6 NMR of 19F PnPs after IEX Figures for direct Ion exchange chromatography Fig.7 Pneumococcal polysaccharide 19F-HPLC profile of pre-IEX Fig.8: Ion exchange chromatogram of pre-HIC (partially purified PnPs) Fig.9: HPLC profile of 19F PnPs after IEX Fig.10: NMR of 19F PnPs after IEX Figures for Ion exchange chromatography followed by HIC Fig.11: HPLC profile of 19F PnPs after IEX Fig.12: HPLC profile of 19F PnPs after HIC Fig.13: NMR of 19F PnPs after IEX-HIC DETAILED DESCRIPTION OF THE INVENTION Definitions: The terms "impurity" and "contaminant", and grammatical variations thereof, are used interchangeably to mean C-polysaccharide. The term "target polysaccharide" is used to refer to a pneumococcal capsular polysaccharide, as described above. The term "chromatography" refers to the process by which a solute of interest, e.g., a polysaccharide of interest, in a mixture is separated from other solutes in the mixture by percolation of the mixture through an adsorbent, which adsorbs or retains a solute more or less strongly due to properties of the solute. The term "hydrophobic interaction chromatography" refers to a method of separating a target based on the strength of its relative hydrophobic interactions with a hydrophobic separation matrix. In this context, "hydrophobicity" is defined as the repulsion between a non-polar compound and a polar environment. The terms "ion-exchange" and "ion-exchange chromatography" refer to a chromatographic process in which an ionizable solute of interest interacts with an oppositely charged ligand linked to a solid phase ion exchange material under appropriate conditions of pH and conductivity, such that the solute of interest interacts non-specifically with the charged compound more or less than the solute impurities or contaminants in the mixture. The contaminating solutes in the mixture can be washed from a column of the ion exchange material or are bound to or excluded from the resin, faster or slower than the solute of interest. "Ion-exchange chromatography" specifically includes cation exchange, anion exchange, and mixed mode chromatographies. The Pneumococcal polysaccharide purification process of the instant invention comprises following steps: (a) lysing bacterial cells with a detergent in a fermentation medium containing a S. pneumococcal bacterium thereby producing a lysate containing a polysaccharide solution and solid cell debri; (b) clarifying the aqueous cell lysate by separating solids from the polysaccharide solution; (c) concentrating the polysaccharide solution by ultrafiltration using a 100K molecular weight cutoff membrane to remove low molecular weight contaminants to form a solution of concentrated polysaccharide; (d) treatment of the solution comprising polysaccharide with a nuclease; (e) precipitation of impurities using ammonium sulphate or DOC-NaCl treatment; (f) diafiltration using 100K molecular weight cutoff membrane